key: cord-0309161-kl8djnsq authors: Schulz, E.; Hodl, I.; Forstner, P.; Hatzl, S.; Sareban, N.; Moritz, M.; Fessler, J.; Dreo, B.; Uhl, B.; Url, C.; Grisold, A.; Khalil, M.; Kleinhappl, B.; Enzinger, C.; Stradner, M. H.; Greinix, H.; Schlenke, P.; Steinmetz, I. title: Association of Naive B Cells with Humoral Response to SARS-CoV-2 Vaccination date: 2021-08-13 journal: nan DOI: 10.1101/2021.08.11.21261898 sha: c78fcce7341c6f7b83362531ab15a39d33fadde7 doc_id: 309161 cord_uid: kl8djnsq Objectives Immunocompromised patients are at risk of severe coronavirus disease 2019 and are considered a high priority for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Humoral vaccination response is impaired in these patients when circulating B cells are lacking. We aimed to analyze B-cell subsets at the time of vaccination to identify potential predictors of humoral vaccination response. Methods Patients (n=120) receiving B-cell-depleting therapy (n=41), those suffering from inborn errors of immunity (n=25) and hematologic malignancies (n=56), and healthy controls (n=79) were vaccinated twice with BNT162b2 or mRNA 1273. B-cell subsets were analyzed prior to vaccination. Two independent anti-SARS-CoV-2 S immunoassays targeting the receptor-binding domain (RBD) or trimeric S protein (TSP) were performed three to four weeks after the second vaccination. Results Seroconversion occurred in 100% of the healthy controls, in contrast to 67% (RBD) and 82% (TSP) of the patients, while only 32% (RBD) and 22% (TSP) achieved antibody levels comparable to those of healthy controls. The number of circulating naive B cell was strongly associated with antibody levels (r=0.761, P<0.001) across all immunosuppressive treatments or conditions. In multivariable analysis, the number of naive B cells was an independent predictor for achieving antibody levels comparable to healthy controls, and receiver operating characteristic analysis predicted that at least six naive B cells per microL were required. Conclusions Assessing the abundance of naive B cells in immunocompromised patients could be useful in predicting the optimal vaccination response. Coronavirus disease 2019 (COVID-19) results in increased morbidity and mortality in 2 immunocompromised patients. [1] [2] [3] Immunodeficiency can be primary (PID) due to underlying 3 genetic causes such as common variable immunodeficiency or secondary (SID) resulting from 4 hematologic malignancies (HM), immunosuppressive therapies, or hematopoietic stem cell 5 transplantation (HSCT). In a recent study of 100 patients with COVID-19 disease, patients with PID 6 and SID demonstrated higher morbidity and mortality than the general population, while the outcomes 7 of individuals suffering from SID were the worst. [1] In patients with HM and COVID-19, a mortality 8 rate of 34% [95% confidence interval (CI): 28-39] has been reported in adults. [4] 9 Due to the high risk of severe COVID-19 in immunocompromised patients, they are considered a high 10 priority for COVID-19 vaccination.[5-9] However, trials of the currently approved COVID-19 11 vaccines have excluded individuals diagnosed with immunodeficiency or malignancy; therefore, 12 information on the efficacy and safety of the vaccines in these patients is sparse. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261898 doi: medRxiv preprint number of circulating B cells or of a certain B-cell subset associated with a humoral vaccination 28 response comparable to healthy individuals is unknown. A marker predictive of vaccination response 29 would aid to schedule vaccinations in the immunocompromised to achieve optimal vaccination 30 response. 31 We hypothesize that specific B-cell subsets present during vaccination are associated with a humoral 32 vaccination response. Herein, we used data from an interim analysis of the prospective, open-label, 33 phase IV CoVVac trial (NCT04858607) to test the hypothesis. 34 Study design and participants 37 We report the data of an interim analysis of the CoVVac trial (NCT04858607), which is an ongoing 38 open-label, phase IV, prospective, monocentric study at the Medical University of Graz, Austria. After 39 approval by the ethics committee of the Medical University of Graz in April 2021 (EK 1128/2021), 40 patients with inborn errors of immunity, hematological malignancies, those receiving B-cell-depleting 41 therapy, and healthy controls were recruited before receiving their first dose of COVID-19 vaccine. 42 The detailed study protocol is provided in the Supplementary Information. In brief, blood was drawn 43 before the first vaccination with BNT162b2 (BioNTech/Pfizer) or mRNA-1273 (Moderna) for 44 peripheral blood mononuclear cell (PBMC) isolation and lymphocyte phenotyping. The second 45 vaccination was administered 21 (BNT162b2) or 28 days (mRNA-1273) after the first. Blood 46 sampling was performed 21-28 days after the second vaccination to analyze the COVID-19-specific 47 antibody response as the primary endpoint. 48 49 It was not appropriate or possible to involve patients or the public in the design, or conduct, or 50 reporting, or dissemination plans of our research. 51 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261898 doi: medRxiv preprint 52 Blood samples from the baseline visit were processed within 4 hours for analysis by flow cytometry. 53 For lymphocyte phenotyping, ethylenediaminetetraacetic acid whole blood was stained for CD3, CD4, 54 CD8, CD45, CD16, CD56, and CD19, as previously described. [25] For B-cell phenotyping, PBMCs 55 were isolated from lithium heparin whole blood by Ficoll gradient density centrifugation. One million 56 PBMCs were incubated with the following antibodies: CD19-VioGreen, anti-IgD-VioBlue, CD24- data were reported as medians (25th-75th percentile) and categorical data as absolute frequencies (%). 76 Correlations and associations between antibody response and other variables were examined using 77 Spearman's rank-based correlation coefficients, rank-sum test, and χ 2 -squared tests. R 2 -statistics were 78 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261898 doi: medRxiv preprint obtained from multiple linear regression models with antibody response as the dependent variable. The 79 optimal cut-off to separate patients with and without vaccination response was assessed by employing 80 a maximized Youden's index within a receiver operating characteristic (ROC) analysis. Logistic 81 models were used for univariate and multivariate modeling of the vaccination response. The Kruskal-82 Wallis test was used for continuous variables when comparing three or more treatment groups. The 83 Kruskal-Wallis H test was used as a post-hoc test to determine between-group differences. 84 87 Complete data of 199 study participants who completed their full vaccination schedule were included 88 in the efficacy analysis. Of these, 79 were healthy participants and 120 were immunocompromised 89 patients. All study participants were vaccinated with mRNA-1273, with only two healthy individuals 90 (1%) receiving BNT162b2. A total of 140 adverse events occurred after vaccination, with the most 91 common being pain at the injection site, headache, fever, and fatigue. Four severe adverse events 92 (hospitalization and death due to HM and bone fractures) were considered unrelated to vaccination. 93 Participant characteristics are detailed in Table 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. of Roche and DiaSorin assays, respectively. Since the clinical significance of antibody levels close to 110 the limit of detection was unclear, we defined more stringent thresholds. In our patients, we defined a 111 "stringent response" as reaching at least the lowest antibody level of the healthy individuals from our 112 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261898 doi: medRxiv preprint cohort (Roche ≥ 1000 U/mL; DiaSorin ≥ 2000 BAU/mL). According to this definition, only 32% 113 (Roche) and 22% (DiaSorin) of patients had a stringent antibody response. This difference was not 114 statistically significant between the two tests (P = 0.108). Patients who received anti-CD20 therapy, 115 including the majority of patients with AIRD, had the lowest rate of stringent response (≤10%). Figure 2C ). Furthermore, this analysis also indicated that the time between the last B-cell-128 depleting therapy and vaccination was also a significant factor correlating with antibody levels. 129 Extending this correlation analysis to the entire study population (Supplementary Table 2 P<0.001, R 2 = 0.123). However, because the age of healthy subjects was significantly lower than that 132 of patients, age appeared to be a significant factor negatively correlated with anti-SARS-CoV-2 133 antibodies after vaccination in the entire study population (Roche: p = −0.209, R 2 = 0.057). 134 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261898 doi: medRxiv preprint Naïve B cells show the strongest association with stringent 148 response 149 To test the association of variables with vaccination response determined by the Roche assay, we 150 performed univariate and multivariate linear regression analyses on the entire study population using 151 the same variables from the correlation analyses. 152 In univariate analysis (Table 3) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261898 doi: medRxiv preprint The multivariable analyses for the entire study population are shown in Supplementary Tables 6 and 7 . 176 The absolute number of naïve B cells remained an independent predictor of stringent antibody 177 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261898 doi: medRxiv preprint response (OR: 1.14 per 10-µL increase, 95% CI: 1.08-1.20, P<0.001), while age was not associated 178 with vaccination response. 179 180 As naïve B cells were the only B-cell subset independently associated with stringent antibody 181 response, we were interested to determine whether our dataset allowed us to estimate a naïve B cell 182 count threshold for stringent antibody response. ROC analysis and non-linear risk modeling predicted 183 that at least six or more naïve B cells per µL were required to generate a stringent vaccine response 184 ( Figures 3A, B) . 185 A second exploratory ROC analysis was undertaken to determine the minimum interval between the 186 last B-cell-depleting therapy, i.e., anti-CD20 antibody therapy or HSCT up to 365 days (n = 53), and 187 vaccination differentiating any seroconversion versus no vaccination response. The optimal cut-off in 188 this population was 116 days or more ( Figure 3C) . In one of the largest studies published on COVID-19 vaccination in patients with HM, Maneikis et al. 198 reported lower median anti-S1 IgG responses after two BNT162b2 vaccine doses in 653 patients with 199 HM than 69 healthy healthcare workers. [16] However, the response was highly heterogeneous, with 200 many patients reaching an antibody response similar to that of healthy controls. Even in the group 201 treated with anti-CD20 therapy, 19% had anti-S1 IgG antibodies in the range of healthy controls. 202 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261898 doi: medRxiv preprint including a 95% confidence interval. In case of A. and B., regression line corresponds to transformed 351 data using x=log((x+1) and y=log((y+1)), respectively. 352 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261898 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 13, 2021. ; https://doi.org/10.1101/2021.08.11.21261898 doi: medRxiv preprint All 256 authors reviewed the draft and approved the final version of the manuscript COVID-19 in patients with primary and secondary 265 immunodeficiency: The United Kingdom experience Clinical impact of COVID-19 on patients with cancer 267 (CCC19): a cohort study Response to "COVID-19 in persons with haematological 269 cancers Outcomes of patients with hematologic malignancies and 271 COVID-19: a systematic review and meta-analysis of 3377 patients COVID-19 vaccine-readiness for anti-CD20-depleting 273 therapy in autoimmune diseases Priority COVID-19 Vaccination for Patients with Cancer while 275 Vaccine Supply Is Limited COVID-19 vaccination: the VOICE for 277 patients with cancer Common Variable Immunodeficiency Disorders, T-Cell 279 Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19 Point of view on the vaccination against COVID-19 in 282 patients with autoimmune inflammatory rheumatic diseases Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in 285 patients with inborn errors of immunity Disease activity and humoral response in patients 287 with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-288 Immunogenicity and safety of the BNT162b2 mRNA COVID-290 19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general 291 population: a multicentre study Glucocorticoids and B Cell Depleting Agents Substantially 293 Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 Seroconversion rates following COVID-19 295 vaccination among patients with cancer Antibody response to SARS-CoV-2 vaccines in 297 patients with hematologic malignancies Immunogenicity of the BNT162b2 COVID-19 299 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: 300 a national prospective cohort study Humoral response rate and predictors of response to 302 BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma Response to first vaccination against SARS-CoV-2 in 304 patients with multiple myeloma Low neutralizing antibody responses in WM, CLL 306 and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine Efficacy of the BNT162b2 mRNA COVID-19 vaccine in 309 patients with chronic lymphocytic leukemia Fifth-week immunogenicity and safety of anti CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on 312 active treatment: preliminary data from a single institution IDSA clinical practice guideline for vaccination of 314 the immunocompromised host Immunogenicity of recombinant hepatitis B vaccine 316 (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants SARS-CoV-2 vaccination in rituximab-treated patients: B 319 cells promote humoral immune responses in the presence of T-cell-mediated immunity A combination of cellular biomarkers predicts failure 322 to respond to rituximab in rheumatoid arthritis: a 24-week observational study Anti-Spike Protein Assays to Determine SARS-325 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays BNT162b2 COVID-19 vaccine is significantly less 328 effective in patients with hematologic malignancies B-cell responses to vaccination at the extremes of age Affinity-based selection and the germinal center response 2019 update of EULAR recommendations for vaccination 334 in adult patients with autoimmune inflammatory rheumatic diseases American College of Rheumatology Guidance for 336 COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version COVID-19 vaccination and antirheumatic therapy None of the contributing authors have a conflict of interest, including specific financial interests, 259 relationships, and affiliations relevant to the topic or materials covered in the manuscript. 260Funding 261None 262 263